Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with Chemoradiotherapy in Limited-stage Small Cell Lung Cancer
NCT04189094Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2020
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of sintilimab in small cell lung cancer (SCLC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival at 2 years. Status: unknown.
02
Drugs
sintilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04189094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04189094.